Sinonasal mucosal melanomas  by Liétin, B. et al.
EO
S
B
T
a
6
b
I
P
i
o
o
1
duropean Annals of Otorhinolaryngology, Head and Neck diseases (2010) 127, 70—76
RIGINAL CLINICAL RESEARCH
inonasal mucosal melanomas
. Liétina, A. Montalbana, C. Louvriera, J.-L. Kemenyb,
. Moma, L. Gilaina,∗
Service d’ORL et de chirurgie de la face et du cou, université d’Auvergne, CHU, BP 69, 58, rue Montalembert,
3003 Clermont-Ferrand cedex 01, France
Service d’anatomopathologie, université d’Auvergne, CHU, BP 69, 63003 Clermont-Ferrand cedex 01, France
KEYWORDS
Mucosal melanoma;
Sinonasal;
Prognosis
Summary
Objectives: Sinonasal mucosal melanomas account for approximately 1% of all melanomas.
These tumors are particularly aggressive, with a recurrence rate between 37 and 54% and a 5-
year survival rate between 20 and 46%. Metastases are frequent. The main objective of this study
was to analyze all of our cases of sinonasal mucosal melanomas and determine any prognostic
factors.
Patients and methods: All our cases of sinonasal mucosal melanoma over a period of 10 years
were included. Ten cases were analyzed. The mean age was 71 years (range: 61—85 years) for
seven women and three men. The clinical, radiological, anatomopathological, and surgical data
as well as the characteristics of disease progression were analyzed. These data were compared
to those reported in the literature.
Results: The mean follow-up was 36.3 months (range: 2—96 months). The 5-year overall sur-
vival was 40%. Seven patients developed local recurrences after a mean follow-up of 16 months
(range: 2—27 months) with associated metastases in three cases. Analysis of the prognos-
tic factors showed that tumors classiﬁed as T1 and limited to the nasal fossae had a better
prognosis.
Conclusion: Sinonasal mucosal melanomas are rare tumors with a high mortality rate. Treatment
of these tumors requires extensive surgical treatment associated with external radiotherapy.
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ntroductionrimary mucous melanoma of the upper aerodigestive tract
s a rare entity [1—2]. These tumors account for 0.5—1%
f ENT tumors [2,3], 0.8% of melanomas [4,5] and 4—5%
f malignant sinonasal tumors [2]. They originate in the
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elanocytes in the ectodermal mucous membranes (neural
rest), whether respiratory cells or stratiﬁed pavimentous
ells [3,6]. In descending order of frequency, their site of
rigin is sinonasal, oropharyngeal, and pharyngolaryngeal
3]. The age at onset is around 20 years later than cuta-
eous melanoma [3,6]. No risk factors are known for this
isease [2,3]. This tumor has a poor prognosis [1,2] and local
ecurrences and distant metastases are frequent [1,6,7].
he 5-year actuarial survival rate varies from 20 to 46%
n the series reported in the literature. The classiﬁcation
served.
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Figure 1 T1-weighted magnetic resonance imaging, coronal
view: tumor of the right nasal fossa and right maxillary sinus
with hypointense and homogenous signal.
Figure 2 T1-weighted magnetic resonance imaging, axial
view with gadolinium injection: heterogenous contrast uptake
of the tumor in the right nasal fossa and right maxillary sinus
with invasion of the pterygomaxillary fossa.
Table 1 Ballantyne classiﬁcation.Sinonasal mucosal melanomas
of these tumors has not been speciﬁcally described by the
AJCC/UICC and the histoprognostic classiﬁcation is currently
being developed.
The present study reports 10 cases of sinonasal mucosal
melanoma analyzed retrospectively. Our main objective was
to report our experience and describe the possible prognos-
tic factors for survival and recurrence, for the most part
absent in today’s literature.
Patients and methods
Patients
Over a 10-year period (1998—2008), 10 cases of sinonasal
mucosal melanoma were treated, involving seven women
and three men. The mean age was 71 years (range: 61—85
years) at diagnosis. Metastases of cutaneous melanoma were
excluded. None of our patients had had a prior diagnosis of
melanoma; all cases were primary melanoma of the nasal
fossae. The main signs were epistaxis (71.4%) and/or nasal
obstruction (57.1%). The other signs were left hemimax-
illa pain (two cases), deformation of the nasal wing and
secondary infection of a nasal fossa. Six patients were sent
by an ORL practitioner after biopsy and anatomopathologic
diagnosis of mucous melanoma. The other four patients were
biopsied in surgery under general anesthesia in our center.
Methods
The data were collected retrospectively from the medical
ﬁles as follows: tumor workup and staging, anatomopatho-
logical analysis, tumor classiﬁcation, immunohistochemical
dosages, and therapy modalities.
Tumor assessment and staging
A nasal endoscopy was systematically done with analysis
of the tumor characteristics (uni- or bilaterality, staining,
location, implantation zone, and volume).
All patients had a computed tomography (CT) examina-
tion of the head and neck with axial, coronal and sagittal
views.
Eight patients had a magnetic resonance imaging (MRI)
examination during the initial workup (Figs. 1—3).
Depending on the case, the workup was completed
by a hepatic ultrasound (three cases), a cervico-thoraco-
abdominal CT (two cases), or a bone scintigraphy (two
cases). One patient had a complete physical examination
including esogastroduodenal ﬁbroscopy, a coloscopic study,
and a dermatological consultation to eliminate cutaneous
melanoma.
Four patients had a PET scan in the initial workup (two
cases), after treatment (one case), and during the disease
course at the ﬁrst recurrence (one case).
Tumor classiﬁcationTumors were staged according to the Ballantyne classiﬁca-
tion based on anatomopathological, clinical, and CT data
(Table 1). Nine patients were classiﬁed in stage I, one patient
in stage II, and none in stage III.
Stage I: tumor conﬁned to original site
Stage II: tumor with regional lymph node metastases
Stage III: tumor with systemic metastases
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Figure 3 T2-weighted magnetic resonance imaging sequence,
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chemical analysis (antiprotein S100 antibodies, antivimentinxial view: heterogenous contrast uptake of the tumor in the
ight nasal fossa and right maxillary sinus with invasion of the
terygomaxillary fossa.
The UICC 2002 TNM classiﬁcation of the nasal and
aranasal cavities was also used for this study (Table 2).
T1: six patients (with tumor size ranging from 3.5mm to
cm).
T2: no patients.
T3: one patient, invasion of the anterior ethmoid (tumor
ize, 4.5 cm).
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Table 2 Clinical characteristics, location, classiﬁcation, treatme
Patients, age Tumor site Classiﬁcation
Ballantyne TN
N1, 67 years Nasoethmoidal I T3
N2, 61 years Septum I T1
N3, 65 years Septum I T1
N4, 66 years Floor I T1
Inferior turbinate
N5, 67 years Inferior turbinate I T1
N6, 62 years Middle turbinate I T1
N7, 73 ans Inferior turbinate I T1
N8, 85 years Maxillary sinus I T4
Posterior extension
N9, 82 years Frontoethmoid maxillary I T4
N10, 76 years Pansinus II T4
PLN: paralateronasal; RT: radiotherapyB. Liétin et al.
T4: three patients, invasion of the pterygomaxillary fossa
one patient) or through lysis of the cribriform plate (two
atients).
opography
he original tumor implantation site was difﬁcult to con-
rm for three patients because of the large size of the
umor at the time of diagnosis (T4). For the patients clas-
iﬁed as T1, the tumor originated in the nasal fossa at
he inferior nasal turbinate (two cases), the nasal septum
two cases), the middle nasal turbinate (one case), and the
unction of the ﬂoor of the nasal cavity and the inferior
urbinate (one case). For the patient classiﬁed as T3, the
umor was located at the middle meatus with extension to
he ethmoid bone. For the two patients classiﬁed as T4,
he tumors had developed at the middle meatus and the
axillary sinus with posterior extension (one case) and at
he middle meatus with fronto-ethmoidomaxillary extension
one case). For the last patient classiﬁed as T4, the tumor
nvaded all the sinuses with extension into the sphenoid (one
ase) (Table 2).
natomopathological analysis
ll patients were diagnosed during a biopsy or a biopsy-
xcision under general anesthesia. Diagnosis of melanoma
as conﬁrmed by anatomopathological and immunohisto-ntibodies, HMB45, Melan-A). Melanin was demonstrated by
ontana-Masson staining or hematoxylin-eosin-saffron stain-
ng. Table 3 illustrates the immunohistochemical marking
btained for the 10 cases.
nt, and course of the 10 cases studied.
Treatment Disease course
M
Transnasal approach Death at 120 months
PLN +RT Death at 42 months
Degloving + RT Death at 25 months
Transnasal approach Tumor recurrence
Alive at 81 months
Transnasal approach Death at25 months
PLN Tumor recurrence
Alive at 76 months
Transnasal approach + RT Alive at 27 months
Transnasal approach Tumor recurrence
Metastases
Death at 9 months
PLN +RT Metastases
Death at 2 months
N2b PLN +RT Visceral metastases
Death at 10 months
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Table 3 Results of tumor immunohistochemical marking.
Patients Antivimentin antibodies Antiprotein S100 HMB 45 Melan-A
N1 ++ ++ ++
N2 ++ ++
N3 ++ ++ + Rare
N4 + ++
N5 ++ ++
N6 ++ ++ ++
N7 + + ++
N8 ++ ++ ++ +
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Immunohistochemical dosages
One patient had a dosage of ICAM-1 and serum interleukin-
2 (IL-2). The IL-2 was administered at 234 pg/ml (norm:
< 10 pg/ml). The ICAM-1 value was nonsigniﬁcant.
Treatment
After staging, a therapeutic decision was made in an
oncology multidisciplinary team meeting and proposed to
the patient. All patients underwent surgery as ﬁrst-line
treatment. Radical resection with margins was performed
via the endonasal approach with endoscopic guidance in
ﬁve cases and via the external transfacial paralateronasal
approach (four cases) or degloving (one case) in the other
ﬁve cases. The surgical specimens were oriented and ﬁxed
in formalin. The anatomopathological study conﬁrmed the
diagnosis, detailing the extension to different structures and
whether or not the surgical margins were invaded. Surgery
was followed by radiotherapy in ﬁve patients (radiother-
apy refused in one case). Postoperative hypofractionated
radiotherapy was administered to three patients (Table 2).
Monitoring
Each case was discussed again in a multidisciplinary team
meeting after surgical resection. In those patients for whom
postoperative radiotherapy was decided, the patient was
seen 3 months after the end of treatment for a whole-body
CT scan. If there was no radiotherapy, follow-up every 2
months was initiated. All consultations included an endo-
scopic nasal exam.
Statistical analysis
Descriptive and regression statistics were used to look for
any possible relations between the quantitative variables.
Survival rates were estimated using the Kaplan-Meier and
Fisher and Yates methods. The beginning date was the date
of diagnosis and the closing date was the date of the last
consultation or the last correspondence if the patient was
alive or the date of death if the patient had died.
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esults
ostoperative histological results
even patients had healthy resection margins during the
xtemporaneous examination conﬁrmed by the ﬁnal anato-
opathological exam. Two patients classiﬁed as T4 had bone
nvasion on the lateral nasal bone (one case) and on the
asal septum (one case). One patient had invasion of the
terygomaxillary fossa; the resection in this location was
nsufﬁcient.
ecurrences and metastases
even patients presented their ﬁrst local recurrence after a
ean 16.1 months (range: 2—27). These were patients ini-
ially classiﬁed as T1 (three cases), T3 (one case), and T4
three cases) (Table 2).
Metastases occurred in six of our 10 patients, with a mean
ime lapse of 11.8 months (range: 1—27). These patients
ere initially classiﬁed as T1 (three cases) and T4 (three
ases). The metastases were located in the cervical lymph
odes in three cases 1, 6, and 25 months after the ini-
ial diagnosis, in the lungs for two patients after 5 and
7 months, and in the liver for two patients after 4 and 5
onths, one case of peritoneal carcinosis 5 months after the
nitial diagnosis, and one patient with melanocyte menin-
itis presenting 8 months after the initial diagnosis. Three
atients with metastatic progression presented associated
ocal recurrence (Table 2).
urvival
ctuarial survival at 2 years was 70%.
ctuarial survival at 5 years was 40%.
he mean survival time was de 41.7 months (range: 2—120
onths).
rognosis factorsumor size
here was no signiﬁcant difference between the different
umors in terms of their size, with p > 0.05. The mean sur-
ival rate was 40.7 months (range: 9—81 months) for a tumor
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ess than 2 cm and 44 months (range: 2—120 months) for a
umor larger than 4 cm. None of the patients in the series
resented a tumor between 2 and 4 cm.
NM classiﬁcation
s regards survival, there was a signiﬁcant difference
p = 0.05) between T1 tumors and T4 tumors, with a mean
urvival rate of 52.3 months (range: 25—81 months) for T1
umors and 7 months (range: 2—10 months) for T4 tumors.
On the other hand, no relation between the initial classi-
cation and the survival time and/or metastases was found.
umor topography
he mean survival rate for melanoma invading the sinuses
as 6 months (range: 2—10 months) and 50.6 months (range:
—120 months) for melanoma located in the nasal fossa. Sta-
istical comparison is difﬁcult because of the small size of
he series.
ype of surgery
he mean survival rate was 52.4 months (range: 9—120
onths) for the tumors operated via the endoscopic
ndonasal approach and 31 months (range: 2—76 months) for
he tumors operated via the external transfacial approach.
ithin the limits of our sample, no signiﬁcant difference
etween the two approaches was found. Statistical compar-
son remains difﬁcult given the absence of homogeneity in
he tumor classiﬁcation.
ealthy resection margins
o signiﬁcant difference (p > 0.05) was found between
ealthy and invaded margins, with a survival of 71.4 months
range: 20—81 months) and 23.4 months (range: 2—76
onths), respectively.
mmunohistochemical results
he immunohistochemical results (Table 3) did not allow us
o isolate prognostic factors.
ostoperative radiotherapy
he time to recurrence was 21 months (range: 5—27
onths) in patients who underwent radiotherapy and 12.2
onths (range: 2—24 months) in absence of postoperative
adiotherapy. No signiﬁcant difference was found between
ypofractionation radiotherapy and classic fractionation
p > 0.05), with time to recurrence 3.7 months (range: 1—10
onths) and 20.2 months (range: 2—27 months), respec-
ively.
iscussion
ucosal melanomas are rare tumors with a poor prognosis
1,7]. They account for 1.3—8% of melanomas in Caucasians
3,8]. Approximately 55% are located in the head and neck
nd in the majority of cases in the sinonasal cavities [8,9].
hey rank third in frequency among the sinonasal malignant
umors and have a poorer prognosis. They are often diag-
osed in subjects between the ages of 60 and 80 years, with
mean age of 65 years [8,10]. The sex ratio reported in the
iterature is equal to 1 or has a slight male predominance
p
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2,6,11]. This contrasts with our series with seven females
nd three males.
The symptoms at presentation are not speciﬁc and the
iagnostic latency can be long [12]. Unilateral epistaxis and
asal obstruction are the major early signs [8,10]. The other
linical signs such as visual impairment, pain and facial
eformation appear later [11]. They are more often dis-
overed at the localized stage [13], in nine cases out of
0 in the present series. In 80% of cases, they originate
n the nasal fossa and in 20% of patients in the sinuses
2—4,10]. Macroscopically, the tumor is sessile or budding,
bstructive and hemorrhagic [14]. Approximately one-third
re achromic [3,4,15].
Diagnosis is based on anatomopathological examination,
ade difﬁcult by the cytological and architectural pleo-
orphism of the different aspects encountered [15]. The
natomopathological diagnosis is based on the afﬁnity of
he tumors for Fontana-Masson stain [14]. The immunohis-
ochemical proﬁle contributes greatly and uses antiprotein
100 antibodies, antivimentin antibodies, HMB45, anti-
elan-A and antityrosinase. The epithelial cell markers are
egative [16].
CT and MRI can evaluate the locoregional and general
umor extension with 3D reconstruction in cases consi-
ering facial rehabilitation [14]. Positron emission tomog-
aphy (PET) CT appears promising in assessing distant
xtension during the initial workup as well as in monitor-
ng these tumors [3,6,12]. Iodine 123-BZA scintigraphy has
een abandoned in favor of PET [2]. It was used for the
ncreased afﬁnity of iodobenzamide for mucosal melanoma
umor cells. Use of technetium lymphoscintigraphy to visual-
ze sentinel lymph nodes could help select patients needing
ymph node curettage to remove lymph node metastases
12]. Complementary examinations can include the search
or cutaneous melanoma to conﬁrm that the sinonasal
ucosal melanoma is indeed a primary melanoma [5,14]. At
he time of diagnosis, the patients most often present lo-
alized disease. Approximately 19% of patients present
ymph node metastases at this time and 10% systemic metas-
ases [3,11,17]. The most frequent systemic metastases are
he lungs, then the liver and the bones [3,4].
There is no TNM classiﬁcation that is speciﬁc to mucosal
elanomas. We used the 2002 TNM classiﬁcation and the
allantyne classiﬁcation. However, we believe the Bal-
antyne classiﬁcation lacks precision and therefore does
ot provide prognoses taking into account tumor size,
istological characteristics, nor those of the tumor site of
rigin or extension [6,8,14]. Ballantyne stage I is divided
nto three subgroups by some authors, taking into account
eep tissue invasion [13]. According to Prasad et al. [13],
hese subgroups could be prognostic. The Clarck and Breslow
ndices cannot be applied to mucosal melanomas because of
he absence of histological limits in the dermis.
As for all the head and neck tumors, the therapeutic
odalities for sinonasal mucosal melanoma combine surgery
nd radiotherapy. The treatment choice should pay parti-
ular attention to quality of life because of the poor overall
rognosis of these tumors. Initial management most often
alls on surgical treatment with wide resection [14,18].
he approach depends on tumor location. Endonasal endo-
copic surgery should be reserved for stage I tumors (UICC)
ith strictly endonasal development. Resection via this
Sinonasal mucosal melanomas 75
Table 4 Oncological results published in the literature and comparison with the present series.
Number of
patients
Mean time to
local recurrence
(months)
Recurrence
rate (%)
Time to
metastases
(months)
2-year
survival
rate (%)
5-year
survival
rate (%)
Mean survival
time (months)
Personal series 10 16.1 70 41.7 70 40 41.7
Bachar et al. [1] 61 60.7 28.7
Kim et al. [4] 27 37 33.9
Bridger et al. [7] 27 14.7 23.2 46
Diaz Molina et al. [8] 17 35.7
Nakaya et al. [10] 60 63.6 31.8
Prasad et al. [13] 39 30.8 41.5
Kharoubi et al. [14] 3 43
Teman et al. [15] 142 54 47 20
Mendelhall et al. [16] 61 50
Cheng et al. [17] 23 3.4 22.3 20
Yii et al. [18] 89 23
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Bozorg Grayeli et al. [23] 1
endonasal approach should be done with sufﬁcient room
around the tumor and in conditions identical to an external
approach. During resection, it is recommended to extend
the margins and multiply the peripheral samples. Endo-
scopic resection was performed in ﬁve cases in our series.
These were stage I tumors, less than 2 cm in size, located
and developing in the nasal fossa. These ﬁve cases involved
histological biopsy and radical resection in a single proce-
dure. Exclusively endoscopic transnasal surgery in managing
melanoma of the nasal fossae remains debatable, however,
because of the possibility of lesions in multiple zones and
the problems verifying tumor margins [19]. In practice, we
believe that these stage I tumors can be treated via an
endonasal approach by experienced operators if the usual
oncological rules are followed (wide resection, healthy mar-
gins, multiple peripheral samples).
Lymph node resection is not a part of conventional treat-
ment because of the low rate of lymph node metastasis
[1,2,8]. It is only done in cases of palpable lymph nodes.
The indications for postoperative radiotherapy are deba-
table [5,8,10] because of melanoma’s low radiosensitivity
[2,14,20]. It should be done if the tumor margins are po-
sitive, in cases of local recurrence, palliative treatment, or
advanced local tumor [3,6,12,21]. Chemotherapy is reserved
for surgical treatment failures and for metastatic patients
[15,17]. Efﬁcacy is limited. Immunotherapy is still at the
research stage [8]. BCG is used in adjuvant treatment and
its efﬁcacy is difﬁcult to evaluate [16,18]. Cytokines (inter-
feron, interleukin-alpha) have been proposed as preventive
treatment after surgery in stage I cancers [14]. The recent
discovery of a high rate of mutation of the BRAF oncogene
in melanocytes has opened research on targeted therapies
on this oncogene.
The risk of local recurrence of these tumors ranges from
37 to 54% in the literature and is associated with a high
risk of metastases [4—6,8]. This explains why the low 5-year
survival rate rarely extends beyond 40% at 5 years (Table 4)
[1,10,15,18,22]. The mean survival for sinonasal melanomas
in the literature is between 20 and 41.5 months [8,13,23].
These data are in agreement with our results.
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Among the prognostic factors, the clinical stage of the
umor may be determinant [16]. This criterion is the only
rognosis for Yii et al. [18], which is in agreement with our
esults. For others, it is contested as the only prognostic
actor [4]. The development of distant metastases is a ne-
ative factor [16]. For others, metastases are independent
f prognosis [8]. In the present series, we found no rela-
ion between the initial tumor stage and the time to onset
f local recurrences and metastases, which argues in favor
f local tumors arising in multiple zones and metastases
volving independently.
There is a difference in survival between melanomas ini-
ially located in the nasal cavities (5-year survival, 30.9%)
nd those initially located in the sinuses (5-year survival, 0)
10], with the tumors developed in the sinuses discovered at
locally more advanced stage. This is in agreement with our
bservations. Age under 50 years and female gender seem
o be unfavorable factors. These two factors are not valid
or other authors [4]. The quality of the tumor resection is
n important prognostic criterion [5,19]. For some authors,
here is a signiﬁcant difference in cases of positive surgical
argins [5,19]. For others, this criterion was not signiﬁcant
10].
From an anatomopathological point of view, a tumor that
s more than 5mm thick, the intensity of the inﬂammatory
eaction, an ulcerated tumor, and high mitotic activity may
e negative factors [4,12,14,16]. The prognosis may also
e poorer in cases of pseudopapillary or sarcomatoid archi-
ecture or undifferentiated cells, vascular invasion, and
ecrosis [4,11,12]. Vascular invasion has also been reported
s a poor prognosis. Pigmented lesions may be a sign of a
etter prognosis [4].
Certain authors found no signiﬁcant difference in terms
f survival between surgery alone and surgery followed by
omplementary radiotherapy [6,10,12,18]. Other authors
uggest that radiotherapy increases local control without
ncreasing survival, independent of tumor stage [1,5—7,16].
adiotherapy provides longer tumor control [7,21].
ypofractionated radiotherapy seems to be preferred
y the majority of authors [6,8,14]. Certain techniques
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uch as IMRT, protons, and particularly image-guided radio-
herapy are promising techniques to optimize radiotherapy
ithout increasing side effects [6,14].
From an immunological perspective, some authors have
escribed prognostic factors. A dosage of interleukin-6
ver 20 pg/ml may predict life expectancy over 6 months
nd a better response to interleukin-2 treatment [2,14].
he Ki67 antigen, a marker of proliferative activity, dosed
n immunohistochemistry may be a prognostic factor in
ucosal melanoma [4]. A Ki67 rate below 35% in tumor cells
ay be a factor for better survival.
onclusion
he only signiﬁcant prognostic factor of survival identiﬁed
n our series was the initial tumor stage classiﬁcation. How-
ver, there seems to be no relation between initial tumor
lassiﬁcation and the risk of local or metastatic recurrence.
Surgery is the ﬁrst-line treatment. The indication for
urgery must take into account the patient’s general health
nd operability criteria. Surgical resection should take wide
argins with multiple peripheral samples. The endonasal or
xternal approach will be chosen based on the tumor size,
ts location, and the surgeon’s experience. Postoperative
adiotherapy is part of standard treatment of head and neck
umors. In sinonasal mucosal melanoma, its indication and
odalities should take into account the tumor stage and the
ostoperative histological results. These tumors continue to
ave a poor prognosis with a high risk of local and metastatic
ecurrence. Hope for improved prognosis rests with multi-
enter studies and the progress expected from molecular
iology.
eferences
[1] Bachar G, Loh SK, O’Sullivan B, et al. Mucosal melanomas of
the head and neck: the Princess Margaret Hospital experience.
Head Neck 2008:1325—31.
[2] Guichard C, Polonowski J, Bost P, et al. Malignant melanomas
of nasal and paranasal cavities: 4 cases report. JFORL
1997;46:27—31.
[3] Saint-Blancard P, Kossowski M. Mélanomes des muqueuses
nasosinusiennes. Presse Med 2006;35:1660—3.
[4] Kim DK, Kim DW, Kim SW, Kim DY, Lee CH, Rhee CS. Ki 67 Anti-
gen as a predictive factor for prognosis of sinonasal mucosal
melanoma. Clin Exp Otorhinolaryngol 2008;1:206—10.[5] Temam S, Mamelle G, Marandas P, et al. Postoperative radio-
therapy for primary mucosal melanoma of the head and neck.
Cancer 2005;103:313—9.
[6] Krengli M, Jereczek-Fossa BA, Kaanders J, Masini L, Beldì D,
Orecchia R. What is the role of radiotherapy in the treatment
[B. Liétin et al.
of mucosal melanoma of the head and neck? Crit Rev Oncol
Hematol 2008;65:121—8.
[7] Bridger AG, Smee D, Baldwin MA, Kwok B, Bridger GP. Expe-
rience with mucosal melanoma of the nose and paranasal
sinuses. ANZ J Surg 2005;75:192—7.
[8] Díaz Molina JP, Rodrigo Tapia JP, Llorente Pendas JL, Suárez
Nieto C. Sinonasal mucosal melanomas. Review of 17 cases.
Acta Otorrinolaringol Esp 2008;59:489—93.
[9] Baek CH, Kim KS, Kang MK. Primary mucosal melanoma
of the nasal cavity. Otolaryngol Head Neck Surg 1996;115:
582—3.
10] Nakaya M, Mochiki M, Takeuchi S, et al. Malignant melanoma of
nasal cavity: report of 16 Japanese patients. Auris Nasus Larynx
2004;31:233—7.
11] Ferraro RE, Schweinfurth JM, Highﬁll GR. Mucosal melanoma
of the sinonasal tract. Am J Otolaryngol 2002;23:321—3.
12] Goerres GW, Stoeckli SJ, von Schulthess GK, Steinert HC. FDG
PET for mucosal malignant melanoma of the head and neck.
Laryngoscope 2002;112:381—5.
13] Prasad ML, Patel SG, Huvos AG, Shah JP, Busam KJ. Primary
mucosal melanoma of the head and neck: a proposal for
microstaging localized. Stage I (lymph node-negative) tumors.
Cancer 2004;100:1657—64.
14] Kharoubi S. Malignant melanoma of the nasal fossae: clini-
cal and therapeutic considerations about three cases. Cancer
Radiother 2005;9:99—123.
15] Ferri E, Pavon I, Armato E, Ianniello F. Primary mucosal
melanoma of the nasal cavity: an uncommon cause of epis-
taxis in the elderly. Otolaryngol Head Neck Surg 2008;138:
797—8.
16] Mendenhall WM, Amdur RJ, Hinerman RH, Werning JW, Villaret
DB, Mendenhall NP. Head and neck mucosal melanoma. Am J
Clin Oncol 2005;28:626—30.
17] Cheng YF, Lai CC, Ho CY, Shu CH, Lin CZ. Toward a better under-
standing of sinonasal mucosal melanoma: clinical review of 23
cases. J Chin Med Assoc 2007;70:24—9.
18] Yii NW, Eisen T, Nicolson M, et al. Mucosal malignant melanoma
of the head and neck: the Mardsen experience over half a
century. Clin Oncol 2003;15:199—204.
19] Laccourreye O, Wagner I, Cauchois R, Jouffre V, Shen W, Brasnu
D. Surgery of primary malignant melanomas of the mucosa of
the nasal fossa and facial sinuses. Ann Otolaryngol Chir Cervi-
cofac 1996;113:163—9.
20] Kardon DE, Thompson LDR. Sinonasal mucosal malignant
melanoma: report of an unusual case mimicking schwannoma.
Ann Diagnostic Pathol 2000;4:303—7.
21] Podboj J, Smid L. Endoscopic surgery with curative intent for
malignant tumors of the nose and paranasal sinuses. EJSO
2007;33:1081—6.
22] Dauer EH, Lewis JE, Rohlinger AL, Weaver AL, Olsen KO.
Sinonasal melanoma: a clinicopathologic review of 61 cases.
Otolaryngol Head Neck Surg 2008;138:347—52.
23] Bozorg Grayeli A, Marianowski R, Wassef M, Tailame G, Tran
Ba Huy P. Amelanotic melanoma of the frontal sinus: a case
report. Ann Otolaryngol Chir Cervicofac 1998;115:23—6.
